ATH-1105 Aids Nerve Health and Motor Skills in Mice, Trial Possible

Use of ATH-1105, a small molecule being developed by Athira Pharma to treat amyotrophic lateral sclerosis (ALS), protected against nerve damage and improved motor function in a mouse model of the disease, according to data shared in a recent company presentation. Athira is planning to file an…

Adding a skin patch containing a Chinese herb mixture called Ji Wu Li (JWL) to standard medications significantly slowed disease progression in people with amyotrophic lateral sclerosis (ALS), according to data from a randomized clinical trial. In the trial, called ALS-CHEPLA (ChiCTR200037353), the benefits of the herbal treatment emerged…

Masitinib, an oral medicine developed by AB Science, has won orphan drug status for treating amyotrophic lateral sclerosis (ALS) in Switzerland. The status is granted by the Swiss Agency for Therapeutic Products (Swissmedic) to therapies that seek to treat life-threatening or chronic diseases affecting no more than…

On Saturday afternoon, I was feeling apprehensive that 2023 would be an even harder year for my husband, Todd, and me than previous ones. Todd’s breathing continues to weaken due to ALS. The beginning of the year is often a time when people take stock of their lives;…

The U.S. Food and Drug Administration (FDA) has granted a Type A meeting to BrainStorm Cell Therapeutics to discuss the agency’s refusal to review NurOwn as a treatment for amyotrophic lateral sclerosis (ALS). According to the FDA, type A meetings are used for “an otherwise stalled product development…

MitoSense and the Centre for Transplantation Technology at Uppsala University are collaborating to harness the power of mitochondria — the energy source for cells — in treating diseases that include amyotrophic lateral sclerosis (ALS), the company announced. MitoSense has developed a patented, first-in-kind mitochondria transplantation technology — coined…

This content is sponsored by Mitsubishi Tanabe Pharma America, Inc. (MTPA) and is intended for U.S. audiences only. Any other present or future content posted by the contributor, not expressly designated as “Mitsubishi Tanabe Pharma America, Inc.  – sponsored content” is not associated with MTPA. Ned Patterson is…

Bosutinib, an inhibitor approved to treat a blood cancer, showed no unexpected safety concerns in people with amyotrophic lateral sclerosis (ALS), with some patients experiencing slower disease progression while on the therapy, results from a Phase 1 clinical trial showed. Larger clinical trials are needed to confirm if bosutinib…

A CRISPR/Cas9 gene editing system can be used to remove the repeat expansion in the C9ORF72 gene, the most common genetic cause of amyotrophic lateral sclerosis (ALS), a new study reports. The system showed positive proof-of-concept effects in mouse models and in human cells, reducing the amount of faulty…

ALS News Today brought consistent coverage of the latest research developments and advances in treatment related to amyotrophic lateral sclerosis (ALS) throughout 2022. We look forward to continuing to serve as a resource for the ALS community in the new year. Here, we’ve compiled a list of the…